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Available online 8 May 2016Background/objectives:Metabolomic proﬁling allows to take a detailed look at lipid metabolism and to study the
levels and roles of its numerous intermediates and products in the pathogenesis of cardiovascular disease (CVD).
This study aimed to investigate the relationship between the metabolic proﬁles of lipid metabolism, arterial
stiffness and hemodynamics in patients with coronary artery disease (CAD) and for healthy controls.
Methods: Serum levels of 186 metabolites were determined with the AbsoluteIDQ™ p180 kit (BIOCRATES Life
Sciences AG, Innsbruck, Austria). The technique of applanation tonometry was used for non-invasive pulse wave
analysis and carotid-femoral pulse wave velocity (cf-PWV) assessments. Principal component analysis (PCA) was
carried out in order to reduce the large number of correlated metabolites to fewer uncorrelated factors.
Results: Elevated levels of C16:1, C18:1, C3-DC(C4-OH), PC aa C40:6, Met-SO/Met, and reduced levels of lysoPC a
C18:2were observed in the CAD group compared to the healthy controls. The cf-PWV showed positive correlations
with C14, C16:1, (C2 + C3) / C0, C2 / C0 and the CPT-1 ratio for the CAD group. Moreover, PCA-derived factor 3
(medium- and long-chain acylcarnitines) proved to be an independent determinant of cf-PWV for these patients.
Conclusions: We demonstrated an independent association between the serum medium- and long-chain
acylcarnitine proﬁle and aortic stiffness for the CAD patients. In addition to the lipid-related classical CVD risk
markers, the intermediates of lipid metabolism may serve as novel indicators for altered vascular function.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Inﬂammation1. Introduction
The levels of the lipid metabolism-related classical biomarkers (i.e.
total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides)
have been estimated for decades to assess the risk for cardiovascular
disease (CVD). However, recent analytical developments (e.g. metabo-
lomics) may enable to extend the current biochemical signature for
both CVD prognosis and risk stratiﬁcation.
Metabolomics is an emerging discipline for proﬁling low-molecular-
weightmetabolites in health and disease. Assessment of themetabolome
provides insight into the actualmetabolic and physiological state of a spe-
ciﬁc cell, organ, or organism. This information allows to gain a more pro-
found understanding of the pathogenic mechanisms that lead to the
morbid state. Furthermore, metabolomic proﬁling could have particular
clinical relevance in early detection, diagnosis and prognosis of both
acute and chronic diseases. It is therefore essential to unlock the true po-
tential of this discipline through linking metabolomic data to known and
validated clinically relevant biochemical and functional biomarkers.land Ltd. This is an open access articlMetabolomic proﬁling allows us to take a more detailed look at
lipid metabolism and to study the levels and roles of its numerous
intermediates and products in the pathogenesis of CVD. In fact,
metabolomic proﬁling of CVD has been in the focus of some recent
large-scale studies. Using a targeted mass spectrometry-based approach,
Shah and colleagues determined metabolic signatures composed of
dicarboxylacylcarnitines, medium-chain acylcarnitines, and fatty acids
that were independently predictive of future CV events in patients at
risk for coronary artery disease (CAD) [1]. A small study in very old
subjects with a high rate of previous CVD also suggested that
medium- and long-chain acylcarnitines could be independently as-
sociated with the subsequent occurrence of CV events [2]. In addi-
tion, certain lysophosphatidylcholines (lysoPC) – such as lysoPC
18:1 and 18:2 – were found to be the risk factors associated with
CAD in a recent large-scale prospective cohort study conducted by
Ganna et al. [3]. The results of these studies clearly indicate that the
signature of metabolic proﬁles may be associated with the increased
risk of CAD and adverse CV outcomes. However, considering the still
emerging role of metabolomics in CV research, all novel associations
between certain metabolites and CVD need to be repeatedly
inspected by different groups using different methodologicale under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to establish the mechanisms by which these metabolites may partic-
ipate in the development of CVD.
Arterial stiffness is characterized by the reduced capability of a
blood vessel to dilate and constrict in response to changes in blood
pressure. It is an independent predictor of all-cause and CV mortality
in a range of different diseases and in the general population [4–7].
Identiﬁcation of metabolic signatures of arterial stiffness in CAD pa-
tients might help better understand the impact of the different low-
molecular-weight metabolites – especially the ones related to
changes in lipid metabolism – on the pathogenesis of CVD.
The main objective of this study was to investigate the relationship
between the metabolic proﬁles of lipid metabolism, arterial stiffness
and hemodynamics in patients with CAD and in clinically healthy
controls.
2. Subjects and methods
2.1. Study population
The present study included 52 male patients with angiographically
conﬁrmedCAD,whowere prospectively recruited from theDepartment
of Cardiology, University of Tartu, Estonia. The exclusion criteria were
any comorbid acute or chronic inﬂammatory disease, diabetes mellitus,
myocardial infarction, cerebrovascular events or revascularization oper-
ation during the preceding 6 months, unstable angina, cardiac arrhyth-
mias, clinically signiﬁcant heart failure or valvular disease, reduced
kidney function (eGFR b 60ml/min/1.73 m2), presence of cancer or en-
docrine pathology.
A total of 40 age- and gender-matched clinically healthy controls from
the same geographic region were identiﬁed through local family physi-
cians. In this group the exclusion criteria were any comorbid acute or
chronic inﬂammatory disease, CAD, cerebral or peripheral atherosclerotic
disease, diabetes mellitus, cardiac arrhythmias, clinically signiﬁcant heart
failure or valvular disease, hypertension, reduced kidney function
(eGFR b 60ml/min/1.73m2), presence of cancer, infectious disease or en-
docrine pathology, or regular use of any medication.
2.2. Study protocol
Lifestyle factors andmedical historywere obtained using an interview
and a self-completed questionnaire. Venous blood samples were drawn
from all subjects between 8 am and 11 am after an overnight fast and ab-
stinence from tobacco, alcohol, tea and coffee. Height and weight were
measured and body mass index (BMI) was calculated. The subjects
were studied after 10 min of rest in a supine position in a quiet,
temperature-controlled room. Brachial blood pressure and carotid-
femoral pulse wave velocity (cf-PWV) were assessed and pulse wave
analysis was made. All hemodynamic measurements were taken
in duplicate and averaged. Each subject gave his written informed con-
sent, and the study protocol was approved by the Ethics Committee of
the University of Tartu.
2.3. Arterial stiffness and central hemodynamics measurements
Central aortic waveforms and other hemodynamic parameters were
evaluated non-invasively with the commercially available SphygmoCor
apparatus (AtCor Medical, Sydney, Australia) [8]. After 15 sequential
high-quality radial waveforms were recorded at the patient's left wrist
using arterial applanation tonometry, a validated generalized transfer
function for calculation of the central aortic pressure waveform was
used [9,10]. Augmentation index (%) was deﬁned as the difference
between the second and ﬁrst systolic peaks of the central arterial
waveform, expressed as a percentage of the central pulse pressure
[11]. Carotid-femoral pulse wave velocity (cf-PWV), a measure of aortic
stiffness, was calculated from the pulse transit time using ECG-gatedcarotid and femoral artery waveform recordings over a known distance
[8]. The distance from the suprasternal notch over the umbilicus to the
femoral artery minus carotid arterial length was used for calculation of
cf-PWV.
2.4. Biochemical analysis
Peripheral venous blood samples were collected in serum separa-
tor tubes (BD SST™ II Advance) and plain tubes (Plain BD
Vacutainer® Tubes) for clinical biochemistry analysis and for
metabolomic analysis, respectively. Thereafter, all samples were centri-
fuged and the supernatant was pipetted into Eppendorf tubes. The
tubes were stored at −70 °C until assayed. Serum myeloperoxidase
(MPO), oxidized low-density lipoprotein (oxLDL) and adiponectin
levels were measured using an enzyme-linked immunosorbent assay
(ELISA) (Myeloperoxidase enzyme immunoassay test kit, BIOCHECK,
Inc. Foster City, CA; Merdcodia Oxidized LDL ELISA, Uppsala, Sweden;
Human Total Adiponectin/Acrp30 immunoassay, R&D Systems
Europe, Abingdon, UK, respectively). The serum levels of interleukin-6
(IL-6) were determined using The Evidence Investigator (Metabolic
Syndrome Array-1, Randox Laboratories, Crumlin, UK). The plasma
concentrations of total cholesterol, LDL cholesterol, HDL cholesterol,
triglycerides, glucose, white blood cell (WBC) count, high-sensitivity
C-reactive protein (hs-CRP) and eGFR were measured in a local clinical
laboratory with automated analyzers using standard laboratory
methods.
2.5. Targeted metabolite quantiﬁcation
The serum levels of metabolites were determined with the
AbsoluteIDQ™ p180 kit (BIOCRATES Life Sciences AG, Innsbruck,
Austria) using the ﬂow injection analysis tandem mass spectrometry
(FIA–MS/MS) as well as liquid chromatography ((LC)–MS/MS) tech-
niques. All measurements were performed as described in the
manufacturer's manual UM-P180. The AbsoluteIDQ™ p180 kit allows si-
multaneous quantiﬁcation of 186 metabolites (acylcarnitines (Cx:y),
amino acids and biogenic amines, hexose, sphingolipids (SMx:y or
SM (OH)x:y), glycerophospholipids (lysophosphatidylcholines (lyso
PCx:y) and phosphatidylcholines (PCaa x:y and PC ae x:y)) from 10 μl
of serum. Lipid side-chain composition is abbreviated as Cx:y,where x de-
notes the number of carbons in the side chain and y denotes the number
of double bonds. Glycerophospholipids are differentiated further accord-
ing to the presence of ester (a) and ether (e) bonds in the glycerolmoiety.
Double letters (aa = diacyl, ae = acyl–alkyl) indicate that two glycerol
positions are bound to a fatty acid residue, while a single letter
(a = acyl or e = alkyl) indicates a bond with only one fatty acid
residue. Identiﬁcation and quantiﬁcation of themetabolites was achieved
usingmultiple reactionmonitoring (MRM) alongwith internal standards.
Calculation ofmetabolite concentrationswas automatically performed by
theMetIDQ™ software (BIOCRATES Life Sciences AG). The concentrations
of all metabolites were calculated in μM. Metabolites below the limit of
detection (n = 35) determined experimentally by BIOCRATES were ex-
cluded from further analysis. The assay procedures of the AbsoluteIDQ™
p180 kit have been described in detail previously [12].
2.6. Statistical analysis
The normality of the distribution of continuous variables was
assessed using the Shapiro–Wilk's test. The metabolite serum concen-
trations were logarithmically transformed as they were positively
skewed. Analysis of covariance was employed to adjust metabolite
levels for BMI and statin use. To account for multiple testing the
Benjamini–Hochberg procedure was used to control false discovery
rate (FDR) at the level of 0.05 [13]. Differences between the two groups
were evaluated by two-tailed Student's t-test and theMann–Whitney U
test, where appropriate. Pearson correlation and Spearman rank
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between continuous variables. Multivariate analysis was performed
using a stepwise (forward followed by backward) multiple linear re-
gression to assess the independent determinants of cf-PWV. Differences
in the proportions between the two groups were assessed using a chi-
square test or Fisher's exact test.
Principal component analysis (PCA) was employed to reduce the
large number of correlated metabolites to fewer uncorrelated factors
both for the CAD patients (Table 2) and the controls (data not shown).
Varimax rotation was carried out to identify interpretable factors; only
the factors that explained at least 5% of total variance were retained.
Also, only the metabolites with absolute factor loadings ≥0.60 were re-
ported as components of a given factor in order to avoid false discover-
ies. Thereafter, for each subject, factor scores (weighted sum of the
standardized metabolites within that factor, weighted on the factor
loading for each individual metabolite) were calculated and included
in the subsequent analyses.
The SPSS software for Windows, version 22.0 (SPSS, Chicago, IL,
USA) was used for statistical analyses.
3. Results
3.1. Baseline characteristics of the study population
Table 1 summarizes the hemodynamic and biochemical characteris-
tics of the two study groups. The groups did not differ signiﬁcantly fromTable 1
Hemodynamic and biochemical parameters of the study groups.
Variable CAD patients
(n= 52)
Controls
(n= 40)
P-value
Age (years) 63.2 ± 9.2 60.3 ± 7.1 0.102
BMI (kg/m2) 27.9 ± 3.5 26.0 ± 3.4 0.013
Height (m) 176.2 ± 6.4 179.4 ± 6.5 0.021
Peripheral SBP (mmHg) 135.0 ± 14.5 129.5 ± 15.0 0.079
Peripheral DBP (mmHg) 78.5 ± 8.0 77.8 ± 7.3 0.674
Central SBP (mmHg) 122.7 ± 11.1 119.3 ± 13.9 0.205
Central DBP (mmHg) 79.7 ± 7.6 78.6 ± 7.3 0.493
MAP (mmHg) 96.0 (91.6–101.4) 92.5 (89.0–100.0) 0.095
Heart rate (bpm) 62.8 ± 8.3 57.8 ± 7.1 0.003
AIx@75 (%) 18.9 ± 7.2 15.3 ± 8.0 0.029
cf-PWV (m/s) 9.7 ± 2.6 8.2 ± 1.7 0.002
WBC count (×109/l) 6.4 (5.2–7.9) 5.1 (4.7–5.8) 0.002
Total cholesterol (mmol/l) 5.1 ± 1.0 5.5 ± 0.9 0.136
HDL-cholesterol (mmol/l) 1.5 ± 0.4 1.6 ± 0.4 0.123
LDL-cholesterol (mmol/l) 3.2 (2.8–4.1) 3.6 (3.3–4.2) 0.076
Triglycerides (mmol/l) 1.2 (0.8–1.6) 1.0 (0.7–1.5) 0.264
oxLDL (U/l) 67.2 (53.5–80.7) 71.4 (59.4–90.0) 0.139
Glucose (mmol/l) 5.8 (5.3–6.3) 5.8 (5.4–6.1) 0.81
hs-CRP (mg/l) 1.3 (0.7–2.8) 1.2 (0.7–2.1) 0.441
MPO (ng/ml) 58.4 (35.3–110.7) 45.8 (27.7–62.6) 0.023
IL-6 (pg/ml) 1.33 (0.74–1.98) 0.95 (0.64–1.29) 0.03
Adiponectin (ng/ml) 5701 ± 2890 7192 ± 3585 0.043
eGFR (ml/min/1.73 m2) 85(73-97) 89(79-93) 0.75
Current smoking, n (%) 13 (24.5) 5 (12.2) 0.186
Medication, n (%)
ACE inhibitors 14 (26.9) 0 (0) b0.001
Angiotensin receptor blockers 11 (21.2) 0 (0) 0.002
Calcium channel blockers 17 (32.7) 0 (0) b0.001
Beta blockers 32 (61.5) 0 (0) b0.001
Diuretics 5 (9.6) 0 (0) 0.066
Antiplatelets 34 (65.4) 0 (0) b0.001
Statins 28 (53.8) 0 (0) b0.001
CAD, coronary artery disease; BMI, bodymass index; SBP, systolic blood pressure; DBP, di-
astolic blood pressure; MAP, mean arterial pressure; AIx@75, augmentation index adjust-
ed to a heart rate of 75 beats per minute; cf-PWV, carotid–femoral pulse wave velocity;
WBC, white blood cell count; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
oxLDL, oxidized low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein;
MPO, myeloperoxidase; IL-6, interleukin-6; eGFR, estimated glomerular ﬁltration rate;
ACE, angiotensin-converting enzyme.each other with respect to mean age, peripheral systolic (PSBP) or dia-
stolic (PDBP) and central systolic (CSBP) or diastolic (CDBP) blood pres-
sure, mean arterial pressure (MAP), eGFR, total cholesterol, HDL
cholesterol, LDL cholesterol, triglycerides, oxLDL, glucose or hs-CRP
levels. Signiﬁcant differences between the groups were found in BMI,
height, heart rate, cf-PWV and heart rate-corrected augmentation
index (AIx@75), as well as in WBC count and serum MPO, IL-6 and
adiponectin levels.
Table 3 presents the serum levels of acylcarnitines and other
potential markers for vascular damage. After adjustment for multiple
testing, BMI and use of statins, higher levels of C16:1, C18:1,
hydroxybutyrylcarnitine (C3-DC(C4-OH)), PC aa C40:6, methionine
sulfoxide/methionine ((Met-SO/Met), an indicator of systemic oxida-
tive stress), and lower levels of lysoPC a C18:2 were observed in the
CAD group compared to the healthy controls.
3.2. Associations of arterial stiffness with metabolites
Univariate analysis revealed that cf-PWV was signiﬁcantly correlat-
ed with age (r= 0.63, P b 0.001) and eGFR (rho=−0.36, P= 0.012)
for the patients with CAD. After adjusting for multiple comparisons,
cf-PWV showed correlations with C14, C16, C16:1, (C2 + C3) / C0
(a measure of overall β-oxidation activity), C2 / C0 and the carnitine to
palmitoyltransferase 1 ratio (the CPT-1 ratio) for the CAD group (see
Table 4). For the healthy subjects, cf-PWV correlated signiﬁcantly only
with age (r = 0.51, P = 0.001), MAP (rho= 0.51, P = 0.001), AIx@75
(r= 0.51, P= 0.001) and glucose levels (rho= 0.38, P= 0.017).
The component scores of factor 3 (acylcarnitines) correlated posi-
tively with cf-PWV for the CAD group (see Table 4). This relationship
retained signiﬁcance after adjusting for potential confounders in a mul-
tiple regression model (R2 = 0.515, P b 0.001, Table 5). For the control
group, none of the metabolomic factors identiﬁed by PCA were signiﬁ-
cantly associated with the parameters of arterial stiffness. However,
it should be noted that the metabolomic factor that was composed
mainly of acylcarnitines showed a borderline signiﬁcant correlation
with cf-PWV (data not shown).
3.3. Arterial stiffness-associated metabolites in relation to hemodynamic
and biochemical parameters
Table 4 depicts the correlation coefﬁcients of themetabolites related
to arterial stiffness for the CAD group. After adjusting for multiple test-
ing the following correlations were observed: factor 3 (acylcarnitines)
showed correlations with HDL cholesterol, glucose and adiponectin;
C14 correlatedwith HDL cholesterol and adiponectin; C16was correlat-
ed with PSBP, CDBP and MAP; (C2 + C3) / C0 and C2 / C0 showed cor-
relations with adiponectin; the CPT-1 ratio correlated with PSBP, PDBP,
CSBP, CDBP, MAP and adiponectin.
4. Discussion
Besides the lipid-related classical CV risk markers, a range of inter-
mediates and products of lipid and amino acid metabolism have
emerged as potential indicators of CVD. Association between tyrosine
and altered arterial function in patients with peripheral arterial disease
was recently shown by our group [14]. Moreover, a large prospective
study of three population-based cohorts identiﬁed phenylalanine - an
immediate precursor of tyrosine - and some unsaturated fatty acids as
potential biomarkers for CV risk [15]. These ﬁndings indicate that
metabolomic studies may help gain a deeper understanding of the mo-
lecular mechanisms of CVD. In addition, although different fractions of
cholesterol and triglycerides are routinely estimated in clinical practice,
they actually cover only a limited part of whole-body lipid metabolism.
Therefore, more detailed metabolomic analysis would hopefully lead to
the discovery of sensitive and speciﬁc novel lipid-related markers for
vascular injury and CVD risk.
Table 2
Principal component analysis for the CAD group.
Factor Description Components Eigenvalue Variance
1 Phosphatidylcholines (PC)/sphingomyelins (SM) PC aa C42:0, PC ae C32:1, PC ae C34:0, PC ae C34:1, PC ae C34:2, PC ae C34:3, PC ae
C36:1, PC ae C36:2, PC ae C36:3, PC ae C36:4, PC ae C38:3, PC ae C38:4, PC ae C38:5, PC
ae C38:2, PC ae C40:2, PC ae C40:3, PC ae C40:4, PC ae C40:5, PC ae C40:6, PC ae C42:4,
PC ae C42:5, PC ae C44:5, PC ae C44:6, SM (OH) C14:1, SM (OH) C16:1, SM (OH) C22:1,
SM (OH) C22:2, SM (OH) C24:1, SM C16:0, Total SM, Total SM-non OH, Total SM-OH
32.64 0.16
2 Phosphatidylcholines/lysophosphatidylcholines
(lysoPC)
lysoPC a C24:0, lysoPC a C26:0, lysoPC a C26:1, lysoPC a C28:0, lysoPC a C28:1, PC aa
C24:0, PC aa C26:0, PC aa C40:2, PC aa C42:6, PC ae C30:0, PC ae C30:1, PC ae C30:2, PC
ae C32:2, PC ae C40:1, PC ae C42:0, PC ae C42:1, PC ae C42:3, PC ae C44:3
22.02 0.10
3 Short-, medium-, and long-chain acylcarnitines (C) C2, C8, C10, C12, C12:1, C14, C14:1, C14:2, C16, C16:1, C16:2, C18:1, C3-DC(C4-OH),
(C2 + C3)/C0, C2/C0
18.06 0.09
4 Amino acids/short-chain acylcarnitine Ala, His, Ile, Leu, Phe, Pro, Thr, Trp, Tyr, Val, alpha-AAA, AAA, BCAA, essential AA,
glucogenic AA, non-essential AA, total AA, C3
12.52 0.06
5 Phosphatidylcholines/lysophosphatidylcholines/PUFA lysoPC a C16:1, PC aa C34:3, PC aa C40:4, PC aa C40:5, PUFA 10.84 0.05
The table displays ﬁve metabolomic factors, derived from principal component analysis, and the associated individual components, description, Eigenvalue and variance. C3-DC(C4-OH),
hydroxybutyrylcarnitine; Ala, alanine; His, histidine; Ile, isoleucine; Leu, leucine; Phe, phenylalanine; Pro, proline; Thr, threonine; Trp, tryptophan; Tyr, tyrosine; Val, valine; AA, amino
acids; AAA, aromatic amino acids; BCAA, branched-chained amino acids; PUFA, polyunsaturated fatty acids.
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time that the proﬁle of serumacylcarnitines is independently associated
with aortic stiffness in patients with CAD. While some previous studies
have shown the predictive value of acylcarnitines on CV events, the
mechanisms behind this relationship remain poorly understood [1–2].
Our ﬁndings link medium- and long-chain acylcarnitines to cf-PWV
and may therefore offer a plausible explanation for the association be-
tween these metabolic intermediates and CVD risk.
Mitochondrial fatty acidβ-oxidation is amulti-step catabolic process
by which fatty acid molecules are broken down into two-carbon
fragments to produce energy. An activated long-chain fatty acid must
be conjugated to a carnitine molecule to be transported across the
inner mitochondrial membrane. These carnitine esters are known as
acylcarnitines. In the mitochondrial matrix long-chain fatty acid
reconjugates with a coenzyme-A molecule after which this activated
form of fatty acid (acyl-coenzyme A) undergoes β-oxidation. However,Table 3
Acylcarnitines and other potential markers for vascular damage.
Variable CAD patients (n = 52) Controls (n = 40) P-valuea
C2 8.23 (6.8–10.8) 7.24 (6.42–8.74) 0.558
C8 0.16 (0.14–0.21) 0.17 (0.14–0.24) 0.393
C10 0.38 (0.32–0.50) 0.38 (0.31–0.52) 0.397
C12 0.13 (0.11–0.16) 0.13 (0.11–0.16) 0.508
C12:1 0.13 (0.11–0.17) 0.13 (0.11–0.17) 0.709
C14 0.03 (0.03–0.04) 0.03 (0.03–0.03) 0.405
C14:1 0.07 (0.05–0.09) 0.06 (0.04–0.08) 0.584
C14:2 0.02 (0.02–0.03) 0.02 (0.02–0.03) 0.596
C16 0.14 (0.11–0.15) 0.12 (0.09–0.12) 0.191
C16:1 0.04 (0.03–0.04) 0.03 (0.02–0.03) 0.046
C16:2 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.887
C18:1 0.15 (0.12–0.17) 0.12 (0.10–0.14) 0.028
C18:2 0.05 (0.04–0.06) 0.04 (0.04–0.05) 0.468
C3-DC(C4-OH) 0.05 (0.04–0.06) 0.04 (0.04–0.05) 0.042
(C2 + C3)/C0 0.27 (0.22–0.33) 0.24 (0.21–0.30) 0.754
C2/C0 0.25 (0.21–0.31) 0.23 (0.19–0.28) 0.724
CPT-I ratio 0.005 (0.005–0.006) 0.005 (0.005–0.006) 0.348
lysoPC C18:2 34.6 (28–41.65) 45.3 (40.23–60.25) 0.018
PC aa C40:6 30.1± 8.9 23.9± 6.6 0.046
Met-SO/Met 0.031 (0.027–0.036) 0.028 (0.024–0.032) 0.022
Concentrations of all metabolites are presented as μM. Data were adjusted for multiple
testing, body mass index and statin use. Abbreviations: CAD, coronary artery disease; C2,
acetylcarnitine; C8, octanoylcarnitine; C10, decanoylcarnitine; C12, dodecanoylcarnitine;
C12:1, dodecenoylcarnitine, C14, tetradecanoylcarnitine; C14:1, tetradecenoylcarnitine;
C16, hexadecanoylcarnitine; C16:1, hexadecenoylcarnitine; C16:2, hexadecadienylcarnitine;
C18:1, octadecenoylcarnitine; C3-DC(C4-OH), 3-hydroxybutyrylcarnitine; (C2 + C3)/C0,
(acetylcarnitine + propionylcarnitine)/carnitine; (C2/C0), acetylcarnitine/carnitine; lysoPC
a C18:2, lysophosphatidylcholineacyl C18:2; PC aa C40:6, phosphatidylcholine diacyl
C40:6; Met, methionine; MetSO, methionine sulphoxide. The mean/median values that
were signiﬁcantly different between the study groups are shown in bold.
a Benjamini–Hochberg adjusted P-value.when the rate of the release of fatty acids from adipose tissue triglycer-
ides overpowers the capacity of β-oxidation, or when the oxidativeme-
tabolism of fatty acids in mitochondria is impaired (e.g. different inborn
errors of mitochondrial β-oxidation), acylcarnitine levels in the blood
will be elevated. An increase in long-chain acylcarnitine levels may
also be induced by hypoxia [1,16–18]. Therefore, it can be hypothesized
that elevated levels of medium- and long-chain acylcarnitines in CAD
patients compared to controls may reﬂect the alterations present at
any step in thismetabolic pathway (release of fatty acids, their transport
into mitochondria, and oxidation in mitochondria). Changes in the
activity of the enzymes that regulate long-chain fatty acid transport
(e.g. carnitine–palmitoyltransferases 1 (CPT-1) and 2 (CPT-2)) could
also occur under hypoxic conditions. Interestingly, we found a positive
relationship between the CPT-1 ratio and cf-PWV for the patients with
CAD. The CPT-1 ratio reﬂects the activity of CPT-1 which is a rate-
limiting enzyme for β-oxidation of long-chain fatty acids [19]. In
addition, positive correlations between cf-PWV, (C2 + C3) / C0 and
C2 / C0 for the CAD group also suggest a potential link between arterial
stiffness and β-oxidation activity for these patients.
Besides its association with arterial stiffness, the PCA-derived factor
3 (acylcarnitines) showed signiﬁcant correlationswith HDL cholesterol,
glucose and adiponectin levels for the CAD group.More speciﬁcally, C16
correlated with PSBP, CDBP and MAP, and therefore seems to reﬂect
changes both in hemodynamics and aortic stiffness for these patients.
Previous studies have demonstrated that C16 might be involved in the
pathology of cardiac ischemia. Its accumulation in themyocardial sarco-
lemma during hypoxia can contribute towards cardiac cell damage and
dysfunction [18,20–21]. Moreover, high plasma levels of C16 have re-
cently been associated with degree of heart failure [22]. The same
study reported that C16 was also independently associated with all-
cause mortality for these patients. However, little is known about the
role of C16:1 in CVD. In the current study, C16:1 levels were higher in
the CADpatients compared to the controls and showed the strongest as-
sociation with arterial stiffness among individual acylcarnitines for the
patient group. C16:1 also seems to be a positive marker for adiponectin
levels.
The clear association between serum acylcarnitines and arterial
stiffness observed for the CAD group is intriguing, yet their true role in
vascular injury remains unknown. It is possible that higher serum
levels of medium- and long-chain acylcarnitines merely reﬂect serious
cardiac ischemia which is the result of more severe atherosclerosis
and increased arterial stiffness. On the other hand, accumulating
acylcarnitines can alter insulin signaling andmay therefore lead to arte-
rial stiffness through induction of insulin resistance [23–24]. Moreover,
insulin resistance itself is accompanied with an increased release of free
fatty acids into the bloodstream [25]. Finally, it can also be hypothesized
that acylcarnitines play a direct causal role in vascular injury, however,
Table 4
Pearson correlation coefﬁcients of the metabolites related to arterial stiffness for the CAD patients.
Factor 3 (acylcarnitines) C14 C16 C16:1 (C2 + C3) / C0 C2 / C0 CPT-1 ratio
Age (years) 0.36 0.27 0.1 0.31 0.25 0.24 0.21
BMI (kg/m2) −0.03 −0.12 0.13 0.03 −0.07 −0.07 −0.1
PSBP (mm Hg) 0.17 0.24 0.36⁎ 0.15 0.28 0.27 0.54⁎⁎
PDBP (mm Hg) −0.08 0.07 0.32 −0.03 0.09 0.09 0.38⁎
CSBP (mm Hg) 0.2 0.21 0.31 0.19 0.28 0.27 0.53⁎⁎
CDBP (mm Hg) 0.03 0.17 0.41⁎ 0.1 0.17 0.18 0.4⁎
MAP (mm Hg) 0.13 0.21 0.39⁎ 0.1 0.18 0.18 0.46⁎⁎
cf-PWV (m/s) 0.49⁎ 0.47⁎ 0.44⁎ 0.5⁎ 0.45⁎ 0.45⁎ 0.47⁎
AIx@75 (%) −0.1 −0.3 −0.27 −0.17 −0.13 −0.13 −0.07
WBC count (×109/l) 0.29 0.3 0.15 0.12 0.09 0.08 0.00
Total chol (mmol/l) −0.11 0.06 0.23 −0.05 −0.05 −0.05 0.18
HDL-chol (mmol/l) 0.41⁎ 0.34⁎ 0.1 0.29 0.19 0.19 0.15
LDL-chol (mmol/l) −0.19 −0.01 0.21 −0.14 −0.17 −0.18 0.18
Triglycerides (mmol/l) 0.01 0.05 0.3 0.08 0.00 −0.01 0.02
oxLDL (U/l) −0.00 0.13 0.29 0.12 0.07 0.07 0.24
Glucose (mmol/l) 0.38⁎ 0.16 0.09 0.17 0.14 0.14 0.00
hs-CRP (mg/l) −0.32 −0.11 −0.05 −0.25 −0.18 −0.18 0.09
MPO (ng/ml) 0.02 −0.13 −0.09 −0.1 0.02 0.03 −0.14
IL-6 (pg/ml) 0.03 0.15 0.23 0.07 0.18 0.17 0.22
Adiponectin (ng/ml) 0.35⁎ 0.44⁎⁎ 0.14 0.24 0.3⁎ 0.3⁎ 0.33⁎
eGFR (ml/min/1.73 m2) -0.33 ‐-0.21 -0.11 −0.21 -0.26 -0.26 -0.22
Abbreviations: CAD, coronary artery disease; C14, tetradecanoylcarnitine; C16, hexadecanoylcarnitine; C16:1, hexadecenoylcarnitine; (C2+ C3) / C0, ratio of short chain acylcarnitines to
free carnitine; C2/C0, ratio of acetylcarnitine to free carnitine; CPT-1 ratio, ratio of long chain acylcarnitines to free carnitine; BMI, body mass index; PSBP, peripheral systolic blood pres-
sure; PDBP, peripheral diastolic blood pressure; CSBP, central systolic blood pressure; CDBP, central diastolic blood pressure; MAP, mean arterial pressure; cf-PWV, carotid-femoral pulse
wave velocity; Chol, cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; oxLDL, oxidized low-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; MPO,
myeloperoxidase; IL-6, interleukin-6; eGFR, estimated glomerular ﬁltration rate. Statistically signiﬁcant correlation coefﬁcients are shown in bold.
⁎ Benjamini–Hochberg adjusted P-value b 0.05.
⁎⁎ Benjamini–Hochberg adjusted P-value b 0.01.
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future experiments.
We also found differences in the levels of PC and lysoPC between the
studied groups. The PC are a class of glycerophospholipids and a major
component of biological membranes. The molecule of PC consists of a
glycerol backbone linked to two fatty acid chains and a phosphocholine.
However, if PCmolecule becomes partially hydrolized, one of these fatty
acids is removed, and lysoPC is generated. Besides their structural
role, PC and lysoPC participate in membrane-mediated cell signaling
[26–27].
The concentrations of lysoPC C18:2 were signiﬁcantly lower in the
patients with CAD. This ﬁnding is in line with a recent large-scale
metabolomic proﬁling study that demonstrated an inverse relationship
between lysoPC C18:2 and CAD [3]. However, the authors suggested
that the association was likely to not be causal. We also observed in-
creased concentrations of PC aa C40:6 in the patients with CAD. The
levels of PC aa C40:6 correlated with total cholesterol for both study
groups, but a positive relationship with HDL cholesterol was observed
only for the CAD group. Interestingly, PC aa C40:6 and lysoPC C18:2
were independently associated with decreased risk of type 2 diabetes
in a recent prospective study conducted by Floegel et al. [28]. In the cur-
rent study, PC aa C40:6 showed positive correlation and lysoPC C18:2
showed negative correlation with cf-PWV among the CAD patients,
however, these relationships lost statistical signiﬁcance after adjust-
ment for multiple comparisons. Yet both metabolites might proveTable 5
Multiple regression model for the CAD patients with cf-PWV as the dependent variable.
Variable Regression coefﬁcient Standard error P value
Age 0.175 0.034 b0.001
hs-CRP 0.511 0.197 0.013
Factor 3 (acylcarnitines) 0.703 0.324 0.036
Statin treatment −1.192 0.602 0.055
R2 = 0.515, P b 0.001. CAD, coronary artery disease; cf-PWV, carotid-femoral pulse wave
velocity; hs-CRP, high-sensitivity C-reactive protein.their potential asmarkers of vascular injury in future studieswith larger
sample size.
Several other metabolic variables showed signiﬁcant positive (C2,
C8, C12, C12:1, C14:1, C14:2, C18:1, C18:2, PC aa C42:0, PC aa C42:2)
and negative (lysoPC a C20:4) correlationswith cf-PWV for the CAD pa-
tients before adjusting for multiple comparisons. Apparently, most of
these variables were medium- and long-chain acylcarnitines. Interest-
ingly, higher levels of lysoPC a C20:4 were shown to be associated
with lower CVD incidence in a previous study by Fernandez and col-
leagues [29]. Although the above relationships between cf-PWV and
metabolites lost statistical signiﬁcance after correcting for multiple
testing bias, these ﬁndings further support the association between
medium- and long-chain acylcarnitines and arterial stiffness reported
in this paper.
Our study has limitations that should be addressed.Wewere unable
to establish cause and effect. The number of subjects recruited was rel-
atively small thus larger studies are warranted to conﬁrm our results.
Only male participants were chosen, hence our ﬁndings cannot be
fully extrapolated to women. We could not withdraw the patients
from their medications and long-term health consequences of smoking
also cannot be ruled out.
In conclusion, we demonstrated an independent association
between serum acylcarnitine proﬁle and arterial stiffening for the CAD
patients. Our ﬁndings suggest that in addition to the lipid-related
classical CVD risk markers, the intermediates of lipid metabolism may
serve as novel indicators for altered vascular function. Yet, further stud-
ies are needed to elucidate the precise role of acylcarnitines and
glycerophospholipids in arterial stiffness.
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